Catena’s CysTyr^™ Conjugation Platform
Unlocks Next-Generation
Multi-Payload Conjugates^™

Catena’s unique platform enables never-before-possible therapeutic structures and revolutionizes antibody-drug conjugates (ADCs)

With an initial focus on solid tumors with high unmet needs, our Multi-Payload Conjugates (MPCs) deliver dual payloads and show preclinical superiority to current standards of care.

Shortcomings of Current ADCs

Limited to a single type of drug/payload

This results in high rates of resistance/relapse, with very few patients showing durable response.

Limited to small molecule payloads

Current conjugation approaches are unable to readily attach payloads beyond a select group of small molecules, limiting therapeutic options.

Premature release of linker-payload from antibody

Unstable attachment to the antibody leads to the majority of linker-payload being released prematurely before reaching the tumor, resulting in a suboptimal clinical profile.

Catena’s Advantages

Unique payloads at multiple sites

Catena’s CysTyr platform enables attachment of multiple kinds of payloads to the same antibody with flexible drug-to-antibody ratio (DAR) and precise conjugation site control.

Payloads of any size and complexity

Catena’s CysTyr platform utilizes our novel C-Y Bond^™ between naturally occurring amino acids (cystine-tyrosine) to create MPCs without limitation of payload size and complexity.

Stability that reduces off-target release

Catena’s C-Y Bond is considerably more stable than traditional maleimide bonds, providing lower off-target release and potentially delivering a superior clinical profile.

Learn more about the science

CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

April 8, 2024 | San Diego, CA

CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM

January 4, 2024 | Berkeley, CA

Catena Biosciences Expands Executive Leadership Team, Appoints Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer

July 27, 2023 | Berkeley, CA

Alert: Unauthorized individuals have been falsely claiming to represent CatenaBio. Learn more